Healthcare Sep 18, 2021 09:08 AM (GMT+8) · EqualOcean
Yiouda health learned on the 18th that recently, Puri benchmark Technology (Beijing) Co., Ltd. (hereinafter referred to as "Puri benchmark") completed a round B financing of 150 million yuan. This round of financing is jointly led by Yipu capital and gaotejia investment, followed by Qichen investment and Huiyuan capital. The old shareholder Innovation workshop and maixing investment added investment. Puri benchmark is a new platform company driven by "multi omics + data mining" and focusing on the differentiated R & D strategy of innovative drugs. It takes multiomics technology, bioinformatics and AI algorithm as the core, and is based on the independently developed AI driven massive multiomics data mining system Aibert ®, It provides pharmaceutical enterprises and biotechnology companies with services such as drug mechanism research, biomarker discovery, biomarker based differentiated R & D strategy, clinical statistics, central laboratory and concomitant diagnosis development. At present, it has formed deep cooperation with a number of domestic and foreign pharmaceutical enterprises and biotechnology companies to help the R & D and approval of a number of new drugs. At the same time, Puri benchmark also forms a cooperative ecology with pharmaceutical enterprises and doctors at the clinical end, so as to provide advanced testing services for patients and help the clinical practice of precision medication. This round of financing will enable Puri benchmark to have a stronger ability to help pharmaceutical enterprise partners build innovative and differentiated pipelines, including systematically improving the company's ability in the field of translational medicine / medicine and accelerating Aibert ® (tumor multi omics data mining system for new drug research and development) platform upgrade.